FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function
about
Whole-exome-sequencing-based discovery of human FADD deficiencyUsing biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndromeAdvances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International WorkshopHow I treat autoimmune lymphoproliferative syndromeBiomarkers and Algorithms for the Diagnosis of Vitamin B12 DeficiencyApproaches to Managing Autoimmune Cytopenias in Novel Immunological Disorders with Genetic Underpinnings Like Autoimmune Lymphoproliferative SyndromeFAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndromeDiagnosis and management of autoimmune cytopenias in childhood.Diabetes and immune thrombocytopenic purpura: a new association with good response to anti-CD20 therapy.Serum Protein Profile in Women With Pregnancy Morbidity Associated With Antiphospholipid Syndrome.Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiencySomatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.The clinical utility of molecular diagnostic testing for primary immune deficiency disorders: a case based review.Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasisTrypanosoma cruzi-induced activation of functionally distinct αβ and γδ CD4- CD8- T cells in individuals with polar forms of Chagas' disease.New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndromeOnset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulationAutoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 childrenIL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndromeThe expanding spectrum of the autoimmune lymphoproliferative syndromesEvans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort.Laboratory evaluation of primary immunodeficienciesImmunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer.Diagnosis of autoimmune lymphoproliferative syndrome caused by FAS deficiency in adults.Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation.Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia.Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutationsOptimal Management of Autoimmune Lymphoproliferative Syndrome in Children.Restimulation-induced cell death: new medical and research perspectives.Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection.Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.Live and let die at TEMRA.Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome.Autoimmune lymphoproliferative syndrome: a multifactorial disorder.Gray platelet syndrome can mimic autoimmune lymphoproliferative syndrome.Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.The molecular signature of murine T cell homeostatic proliferation reveals both inflammatory and immune inhibition patterns.Increased IL-17 and IL-21 producing TCRαβ+CD4-CD8- T cells in Chinese systemic lupus erythematosus patients.
P2860
Q24309135-C2E9E0F3-890F-458D-B9E3-8294B9111AE2Q24623046-FEBCCFC2-3A83-4AE3-8EB4-C0E6AF6C9E1FQ24623371-24FBD3EF-1B0C-4515-96C3-509549C2355AQ24632569-414C06E8-8699-4B5C-A277-FD47A8BE2F18Q24633207-A472FAAF-9B01-4979-9FC0-A977ABF5BD3CQ26742072-32797406-1A75-4520-A4AF-653654DEB2DFQ26799956-E460F804-C411-44E5-A9D8-77EFB4717EADQ28235519-7500C759-157E-4B08-8AAD-D3B8236EA6F6Q33411497-2EDCEDD2-7A69-4283-A849-B703A7625A69Q33413423-46C7340E-F572-4E8E-B0B7-9F2B3358BB31Q33604935-B680AA09-9CB5-412F-8152-AF6518640F31Q33910884-90E7088F-4FCE-46BA-BEC2-04E32A9476E8Q33944255-E7C6DDF4-3898-4A3B-B1B6-3D48F7055150Q33992261-CD5C86CB-319B-4201-B9CD-0B551D6773BCQ34149957-E8CA2579-D13B-4900-B9E6-4A5E98265A6CQ34177376-56626C00-0745-48EA-ADCE-B2E83E7931E6Q34239719-375DFF34-0EE7-4F66-917D-0693750C8390Q34428954-A8844D56-2891-450F-820B-EBF707E84E3EQ34445129-6C1AF00D-E5D4-4728-8C35-5886393EC6BDQ34890377-92B4284C-7D8B-4E21-9EA6-8DBB8FF6A3C5Q35130847-AD595146-8881-405E-B21C-03F5E58C5213Q35619447-C472A6AA-4BD7-4C8C-834F-D44EEFA1FC7CQ36101764-604D72A6-3B82-4CC2-AF1C-33BBF993EF6DQ36142583-CABCE2BE-6325-4DD0-AB79-B7E22AC9DEDEQ36557519-3DE17D00-A9A2-4961-BB86-B57EDBF81859Q36862333-7C39E909-0E7C-4429-AF34-F12408FE44CAQ37298573-524F966D-A3E0-4485-9291-4508EA99047EQ37377927-E28F2518-CF9C-409E-A2ED-8635CC940DA5Q37670054-B25A71BC-46DD-4FA9-8515-7D1956E4290DQ38823961-3A444610-2091-4DF1-8DFE-A34E5D82AAF0Q39277444-1972055F-14DD-444C-B0EC-74A87A4F2D73Q40323202-9CF33ED7-9A22-4CE4-A95F-CE2025A410B4Q41428240-A6F4762B-486E-4624-A9E1-3FBF4D0790E7Q41901585-0EAEF1D8-E147-4F8F-958A-26DBD90369C8Q42325007-2CC484E8-75F7-4325-B8B6-5855EC592C2EQ42392801-A84C6F93-0B86-4B4D-AC01-653C28A4FBF9Q43124182-E1084B16-B977-45D1-BCD5-6FA49107504FQ47151016-FBAA96F1-F4A9-4C76-B4C5-F89203826B7DQ50975972-909ED723-CAA9-466F-8088-BAE1C3F46CA5Q51752326-E5321CC8-0D7D-4028-AD5F-1353F897B583
P2860
FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
FAS-L, IL-10, and double-negat ...... ated with FAS loss of function
@ast
FAS-L, IL-10, and double-negat ...... ated with FAS loss of function
@en
FAS-L, IL-10, and double-negat ...... ated with FAS loss of function
@nl
type
label
FAS-L, IL-10, and double-negat ...... ated with FAS loss of function
@ast
FAS-L, IL-10, and double-negat ...... ated with FAS loss of function
@en
FAS-L, IL-10, and double-negat ...... ated with FAS loss of function
@nl
prefLabel
FAS-L, IL-10, and double-negat ...... ated with FAS loss of function
@ast
FAS-L, IL-10, and double-negat ...... ated with FAS loss of function
@en
FAS-L, IL-10, and double-negat ...... ated with FAS loss of function
@nl
P2093
P50
P3181
P1433
P1476
FAS-L, IL-10, and double-negat ...... ated with FAS loss of function
@en
P2093
Alina Ferster
Benoit Florkin
Bénédicte Neven
Caroline Thomas
Catherine Schaffner
Claire Fieschi
Claire Galambrun
Francoise Le Deist
José Barbot
Maria S Loffredo
P304
P3181
P356
10.1182/BLOOD-2008-09-179630
P407
P50
P577
2009-03-26T00:00:00Z